vildagliptin galenicum tablett
galenicum health s.l.u. - vildagliptiin - tablett - 50mg 30tk; 50mg 336tk; 50mg 90tk; 50mg 112tk; 50mg 180tk; 50mg 60tk
dutasteride galenicum pehmekapsel
galenicum health s.l.u. - dutasteriid - pehmekapsel - 0,5mg 50tk; 0,5mg 90tk; 0,5mg 30tk; 0,5mg 60tk
adrenalin galen süstelahus
galen ilac sanayi ve tic. a.s. - epinefriin (adrenaliin) - süstelahus - 1mg 1ml 1ml 10tk
triamgalen salv
paul w. beyvers gmbh - triamtsinoloon - salv - 1mg 1g 50g 1tk
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaktsiinid - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaktsiinid - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaktsiinid - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
nobilis rt+ibmulti+nd+eds süsteemulsioon
intervet international b.v. - newcastle'i tõve viirus-/paramüksoviirusvaktsiin+lindude nakkava bronhiidi viirusvaktsiin+lindude adenoviirusvaktsiin+lindude rinotrahheiidi viirusvaktsiin - süsteemulsioon - 1annus 500annus 1tk
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaktsiinid - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.